Cue Biopharma
CUE
78 hedge funds and large institutions have $50.5M invested in Cue Biopharma in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 13 closing their positions.
428% more call options, than puts
Call options by funds: $586K | Put options by funds: $111K
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
24% more funds holding
Funds holding: 63 → 78 (+15)
17% more capital invested
Capital invested by funds: $43M → $50.5M (+$7.51M)
0.14% more ownership
Funds ownership: 0.93% → 1.07% (+0.14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.49M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.55M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.08M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$992K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$4.11M |
| 2 |
Millennium Management
New York
|
-$653K |
| 3 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$536K |
| 4 |
CC
Carlson Capital
Dallas,
Texas
|
-$470K |
| 5 |
VC
Voss Capital
Houston,
Texas
|
-$446K |
CUE Hedge Fund Activity: Q2 2023 in Review
78 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2023, worth a combined $50.5M — up 17% from $43M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CUE positions and 13 closed out — a net gain of 16 holders — while 23 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $5.49M. The largest seller was Prosight Management, exiting entirely with an estimated $4.11M sold.
- 78 institutional investors held Cue Biopharma (CUE) as of Q2 2023, up from 63 in Q1 2023.
- Funds reported $50.5M of Cue Biopharma stock for Q2 2023, up 17% quarter-over-quarter.
- 29 funds opened new Cue Biopharma positions in Q2 2023 and 13 closed out, a net change of +16 holders.
- The largest Cue Biopharma buyer in Q2 2023 was BlackRock, an estimated $5.49M added.
- The largest Cue Biopharma seller in Q2 2023 was Prosight Management, an estimated $4.11M sold.
Based on aggregated 13F filings for Q2 2023.